PD-325901

· Pfizer

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for PD-325901, covering 2009-03-17 to 2013-09-13. Get the full timeline:

Most recent: Clinical Trial Update: MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma. [Phase 1, Phase 2]